

**MULTISCREEN™ STABLE CELL LINE  
HUMAN RECOMBINANT CX3CR1 RECEPTOR**

**Data sheet**

**PRODUCT INFORMATION**

**Catalog Number:** CG1008

**Lot Number:** CG1008-112811

**Quantity:** 1 vial ( $2 \times 10^6$ ) frozen cells

**Freeze Medium:** Sigma Freezing Medium (C-6164)

**Host cell:** HEK293T Gqi5

**Transfection:** Expression vector containing full-length human CX3CR1 cDNA (GenBank Accession Number NM\_001337) with FLAG tag sequence at N-terminus

**Recommended Storage:** Liquid nitrogen upon receiving


**Propagation Medium:** DMEM, 10% FBS, 1  $\mu$ g/mL puromycin, 250  $\mu$ g/mL hygromycin

**Stability:** Stable in culture for minimum of two months


**Background:** CX3CR1, (CX3C-chemokine receptor 1, fractalkine receptor or GPR13) is a receptor for the CX3C chemokine fractalkine. CX3CR1 is expressed in cytotoxic effector lymphocytes, including natural killer cells, cytotoxic T lymphocytes and macrophages. Soluble fractalkine causes migration of these cells, whereas the membrane-bound form captures and enhances the subsequent migration in response to secondary stimulation with other chemokines. Furthermore, stimulation through membrane-bound fractalkine activates natural killer cells, leading to increased cytotoxicity and interferon-gamma production. Fractalkine is involved in the pathogenesis of various clinical disease states or processes, such as atherosclerosis, glomerulonephritis, cardiac allograft rejection and rheumatoid arthritis. In addition, polymorphisms in CX3CR1, which reduce its binding activity to fractalkine, have been reported to increase the risk of HIV disease and to reduce the risk of coronary artery disease.

**Application:** Functional assays

**Figure 1**



**Figure 2**



**Figure 1.** Dose-dependent stimulation of calcium flux upon treatment with ligand, monitored with FlexStation. **Figure 2.** Receptor expression on cell surface measured by flow cytometry (FACS) using an anti-FLAG antibody. Thin line: parental cells; thick line: receptor-expressing cells.

**References:**

Imai *et al.* (1997) Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. *Cell* 91:521-530.

Garin *et al.* (2003) Two novel fully functional isoforms of CX3CR1 are potent HIV coreceptors. *J Immunol* 171:5305-5312.

**FOR RESEARCH USE ONLY.**

© 2005 Multispan Inc. All rights reserved. No part of this document may be reproduced in any form without prior permission in writing.

www.multispaninc.com  
sales@multispaninc.com  
support@multispaninc.com

Ver. October 2005

Phone: +1 (510) 887-0817  
Fax: +1 (510) 887-0863  
26219 Eden Landing Road  
Hayward, CA 94545-3718  
U.S.A.